CJC-1295 No DAC 5 mg

About CJC-1295 No DAC

CJC-1295 No DAC, also called Mod GRF 1-29, copies the first 29 amino acids of human growth hormone-releasing hormone (GHRH), the stretch that carries the hormone's full activity, and swaps four of them to slow breakdown.¹⁹ Without the swaps, the same 29 amino acids are sermorelin.¹⁴⁹ GHRH tells pituitary cells to release growth hormone, which then raises IGF-1.¹⁹ The CJC-1295 name first belonged to a long-acting version with a drug affinity complex (DAC); the form without it appears to be first described in a 2010 report on a product seized in Norway.⁴⁶¹

This page lists CJC-1295 No DAC for sale as a 5 mg research vial, with the CJC-1295 No DAC price and stock for each origin in the selector above. Before you buy CJC-1295 No DAC for a study, read What is CJC-1295 No DAC? for the safety record and regulatory history.

Research highlights

• Related analog, 10 healthy men (1994): adding only the D-alanine swap at position 2 to GHRH(1-29) lengthened its disappearance half-time during IV infusion from 4.3 to 6.7 minutes.⁷
• Seized product, Norway (2009): mass spectrometry found a 29-amino-acid peptide with a C-terminal amide whose sequence fit the peptide marketed as CJC-1295;⁶ FDA notes it had no DAC.¹
• Seized powders, Denmark (2019 report): some held analogs of modified GRF 1-29 with an extra glycine at the N-terminus.⁸ FDA cites it when warning of inconsistent CJC-1295 naming.¹
• The DAC form, healthy adults aged 21 to 61 (2006): one injection raised mean growth hormone 2 to 10 times for 6 days or more and IGF-1 1.5 to 3 times for 9 to 11 days; FDA says these results cannot be extrapolated to the form without DAC.⁵¹
• Evidence grading (2026 review): the no-DAC form sits in tier D, the lowest, for having no peer-reviewed human studies; the DAC form is tier B and tesamorelin tier A.⁹

Regulatory status

No FDA-approved drug contains any form of CJC-1295, and FDA found none approved in 12 other countries or by the European Medicines Agency.¹ On December 4, 2024, FDA's compounding advisory committee voted 13 to 0 against adding the free base, this peptide, to the 503A bulks list.¹⁰ FDA's safety-risk page places CJC-1295 among former category 2 substances withdrawn by their nominators, citing immunogenicity and serious adverse events such as increased heart rate and systemic vasodilatory reaction.¹¹

In an August 2026 warning letter, FDA said research-use labels did not stop it treating an online seller's peptides as drugs for human use.¹² WADA bans CJC-1295 at all times under S2.2.4.¹³

Handling and storage

Vendor data cited by FDA describe the free base as only slightly water-soluble but soluble in 1% acetic acid, and the acetate as soluble in water at 5 mg/mL.¹ At that rate, 5 mg of the acetate needs at least 1 mL to dissolve fully. The listing does not name the salt form, so check the lot's certificate, if one is available, before choosing a diluent. The steps are in the reconstitution guide, and the reconstitution calculator works out the concentration.